The global impetigo drug market is anticipated to grow at a considerable CAGR of 7.1% during the forecast period (2022-2028). The key factors driving the growth of the impetigo drug market are an increase in infectious diseases, along with an increase in hospital-acquired infections. For instance, the information provided by the University of Oxford highlighted the fact that more than 1.2 million people died in 2019 as a direct result of antibiotic-resistant bacterial infections. Moreover, according to National Center for Biotechnology Information (NCBI), in August 2021, impetigo is responsible for about 10% of all skin issues in children. So, the majority of producers are concentrating on product development and the development of new ointments, pills, and lotions that can heal the disease faster and with fewer adverse effects. For instance, in December 2021, LEO Pharma A/S had received the FDA approval of tralokinumab-Idrm for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older.
Browse the full report description of “Global Impetigo Drug Market Size, Share & Trends Analysis Report By Drug Class (Fusidane, Quinolones, Sulfonamides, and Tetracycline), and By Distribution Channel (Online and Offline) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/impetigo-drug-market
Additionally, rising demand for broad-spectrum antibiotics, increased use of over-the-counter medications, and rising healthcare expenditures, along with R&D activities to improve the quality of drugs for impetigo treatment are some of the factors driving the impetigo drug market. Moreover, government attempts to accelerate regulatory approvals for innovative pharmaceuticals and development potential in emerging markets, on the other hand, are projected to provide attractive opportunities for market expansion.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Drug Class
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including Cutanea Life Sciences, GlaxoSmithKline plc., LEO Pharma A/S, Medimetriks Pharmaceuticals Inc., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Impetigo Drug Market Report Segment
By Drug Class
By Distribution Channel
Global Impetigo Drug Market Report Segment by Region
North America
• US
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/impetigo-drug-market